Oncology Data Advisor

The treatment of esophagogastric cancer is undergoing a profound transformation. In this episode, Yelena Janjigian, MD (MSKCC), discusses how perioperative chemoimmunotherapy and precision biomarkers are redefining the standard of care. Key highlights include: - The Perioperative Shift: Why starting immunotherapy before surgery is achieving unprecedented pathologic responses. - Precision Testing: The essential role of MSI, PD-L1, HER2, and CLDN18.2 testing for every patient. - Avoiding Understaging: Why clinical evaluation must go beyond imaging to prevent missed therapeutic opportunities. - Multidisciplinary Success: The critical need for surgeon-oncologist communication before the first incision. Tune in to learn why "cure" is the new benchmark in localized disease and how to integrate these advances into your clinical practice today. Interested in the complete CE activity? Complete Module 1: https://bit.ly/45u106o Complete Module 2: https://bit.ly/3HtOziO